Shionogi & Co., Ltd. (Head Office: Osaka; President: Isao Teshirogi) today announces that it launched Fluitran® 1mg (generic name: trichlormethiazide), thiazidal antihypertensive diuretics, in Japan on May 15.

Fluitran® is an oral preparation of thiazidal antihypertensive diuretics, trichlormethiazide, which had been developed and marketed in the U.S. in 1960 by Schering-Plough U.S. It can reduce the strain on the hearts in hypertensive patients by inhibiting Na⁺ ion and water reabsorption from renal distal tubules, and by excreting excess water from the body, and increasing urine output.

In the guideline 2009 (JSH2009) for hypertensive treatments issued by The Japanese Society of Hypertension, the combination therapy of renin-angiotensin system suppressive drugs including angiotensin receptor blocker (ARB) and a low dose of antihypertensive diuretics is recommended from the viewpoints of synergistic action of antihypertensive effects and less side-effects related to electrolyte and glucose metabolism. Shionogi has already made a sale of Fluitran® 2mg since 1960. Therefore, by providing a lower dosage formulation, Fluitran® 1mg to clinical practice, Shionogi could further contribute to improve convenience of patient and a stronger antihypertensive effect could be expected by combination with Irbetan®, which is an ARB Shionogi has provided.

By launch of Fluitran®, Shionogi can enrich antihypertensive drugs such as Irbetan® with evidence of kidney protection effect and Landel®, continual calcium channel blocker, used as a basal drug in the large-scale clinical trial “JATOS”. And then, it could offer the most suitable tailor maid treatments for hypertensive patients with chronic kidney diseases (CKD). Shionogi is continuously committed to all activities in research and development and drug information after launching drugs that will benefit more hypertensive patients.
Fluitran® 1mg Product Overview

Product Name: Fluitran® 1mg tablets
Generic Name: Trichlormethiazide
Effect: Essential hypertension, Renal hypertension, Malignant hypertension, Cardiac edema (congestive cardiac failure), Renal edema, Hepatic edema, Premenstrual syndrome
Approval Date: January 14, 2009
NHI Drug Price Listing: May 15, 2009
Launch Date: May 15, 2009
Price: 6.30 (Yen)

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:
Corporate Communications Department
Shionogi & Co., Ltd.
Telephone: +81-6-6209-7885
Fax: +81-6-6229-9596